Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Open-Label, Dose-Escalation and Dose-Expansion Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)

NCT03647800 is registered in ClinicalTrials.gov with Aptevo Research and Development LLC as lead sponsor.

NCT NCT03647800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03647800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Open-Label, Dose-Escalation and Dose-Expansion Study of APVO436 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndrome (MDS)
Lead sponsor
Aptevo Research and Development LLC
Phase
Phase 1
Overall status
Unknown status
Start date
December 13, 2018
Completion date
June 15, 2023
Enrollment
136 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds